Please assess the completion status of the following clinical trial:

Trial Title: S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed stage III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer~  * Adenocarcinoma~ * Large pelvic mass and/or bulky abdominal disease and/or malignant pleural effusion~ * Pleural effusion only for stage IV (parenchymal, liver, lung, or other distant metastases not allowed)~ * No borderline or low-malignant potential tumors~* Optimal cytoreduction clinically deemed unlikely~* CA 125 at least 70 units/mL~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2 times upper limit of normal (ULN)~* SGOT no greater than 2 times ULN~Renal:~* Creatinine clearance at least 50 mL/min~Cardiovascular:~* No congestive heart failure or cardiac arrhythmia~* No myocardial infarction or angina within past 6 months~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No severe gastrointestinal symptoms (i.e., partial obstruction) and/or gastrointestinal bleeding~* No grade 2 or greater sensory neuropathy~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer in complete remission~* No active or uncontrolled infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy for this cancer~Chemotherapy:~* No prior chemotherapy for this cancer~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior pelvic radiation for this cancer~Surgery:~* See Disease Characteristics~* Prior exploratory laparotomy allowed provided an aggressive tumor debulking procedure was not performed (e.g., bilateral salpingo-oophorectomy/total abdominal hysterectomy with omentectomy)~* Prior salpingo-oophorectomy and/or partial omentectomy allowed~Other:~* No other concurrent anti-cancer therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- chemo/debulking surgery/IP chemo (Type: EXPERIMENTAL): neoadjuvant chemotherapy (carboplatin and paclitaxel) followed by debulking surgery followed by intraperitoneal chemotherapy (carboplatin and paclitaxel)

Based on this trial design, predict the completion outcome and termination type (if applicable).